COLL logo

Collegium Pharmaceutical, Inc. Common Stock

COLL

COLL: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

more

Show COLL Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of COLL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by COLL's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jul 20, 2023 Issue: Health Issues
  • $10,000 Apr 17, 2023 Issue: Health Issues
  • $60,000 Jan 19, 2022 Issue: Health Issues
  • $60,000 Oct 20, 2021 Issue: Health Issues
  • $60,000 Jul 20, 2021 Issue: Health Issues
  • $10,000 Apr 20, 2017 Issue: Health Issues
  • $20,000 Jan 23, 2017 Issue: Health Issues
  • $30,000 Oct 14, 2016 Issue: Health Issues
  • $40,000 Jul 19, 2016 Issue: Health Issues
  • $10,000 Apr 20, 2016 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Jun. 02, 2020
  • Patent Title: Process of making stable abuse-deterrent oral formulations May. 12, 2020
  • Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Jan. 07, 2020
  • Patent Title: Abuse-deterrent drug formulations Jan. 07, 2020
  • Patent Title: Process of making stable abuse-deterrent oral formulations Jan. 29, 2019
  • Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Jun. 26, 2018
  • Patent Title: Process of making stable abuse-deterrent oral formulations May. 15, 2018
  • Patent Title: Abuse-deterrent drug formulations Sep. 19, 2017
  • Patent Title: Process of making stable abuse-deterrent oral formulations Aug. 22, 2017
  • Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Jun. 20, 2017
  • Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Mar. 14, 2017
  • Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Feb. 02, 2016
  • Patent Title: Abuse-deterrent pharmaceutical compositions of opiods and other drugs Jun. 02, 2015
  • Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Sep. 23, 2014
  • Patent Title: Abuse-deterrent drug formulations Jun. 24, 2014
  • Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Oct. 15, 2013
  • Patent Title: Pharmaceutical compositions for sleep disorders Aug. 20, 2013
  • Patent Title: Abuse-deterrent drug formulations May. 28, 2013
  • Patent Title: Modified release compositions of milnacipran Sep. 20, 2011
  • Patent Title: Abuse-deterrent drug formulations Aug. 10, 2010
  • Patent Title: Modified release compositions of milnacipran Apr. 27, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of COLL in WallStreetBets Daily Discussion

COLL News

Recent insights relating to COLL

CNBC Recommendations

Recent picks made for COLL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in COLL

Corporate Flights

Flights by private jets registered to COLL